Epic Sciences' Platform Capable of Single Cell CTC Identification Sequencing in Late Stage, Metastatic Cancer

Unbiased CTC detection and analysis from Epic Sciences™

Epic Sciences to Present at World CDx Boston 2015

Epic Sciences Appoints Dave Henderson as Chief Information Officer

World CDx - Boston 2015

Murali Prahalad, Ph.D., president and CEO, will give a presentation entitled “Matching the Spectrum of Cellular Heterogeneity to the Spectrum of Therapeutic Response in Cancer” at World CDx Boston 2015.

Epic Sciences' Dr. Dena Marrinucci Is Recognized as an Honoree of MIT Technology Review's Annual INNOVATORS UNDER 35 List

Epic Sciences Publication Validates Unbiased Detection of Circulating Tumor Cells (CTCs) from a Liquid Biopsy

Join Epic at Relay for Life on August 15 and 16

Epic's CSO Dena Marinucci Named to PharmaVoice 100

Epic Sciences Appoints Dr. Greg Critchfield to Board of Directors

Epic Sciences Expands Partnership with LabCorp to Provide Circulating Tumor Cell Analysis and Support Oncology Clinical Trials in Asia

Epic Sciences Expands Silicon Valley Bank Credit Facility

Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity

Epic Sciences to Present at UBS Global Healthcare Conference

GenomeWeb: Epic Sciences Collaborators Share Data at AACR on Single Cancer Cell Analysis, CTC Biomarker Detection

Epic Sciences Demonstrates Single Cell Genetic Analysis for Circulating Tumor Cells

Celebrating an Epic Year of Service!

March 18 Is Kick Butts Day…Two Ways to Fight Lung Cancer

Epic Sciences and The Prostate Cancer Clinical Trials Consortium Collaborate to Advance Therapeutic Development

On International Women’s Day: Q&A with CSO Dena Marrinucci

ASCO GU 2015

Epic’s collaborators are presenting three studies at the 2015 ASCO Genitourinary Cancers Symposium held in Orlando, Fla., that demonstrate how the Epic Sciences no cell left behind™ platform could be used as a blood test for certain types of metastatic prostate and bladder cancers — liquid biopsies to predict which patients will best respond to certain therapies before they are treated.

This Week at ASCO GU 2015: Detecting PD-L1 in Metastatic Bladder Cancer

This Week at ASCO GU 2015: New Potential Diagnostic Biomarker for Neuroendocrine Prostate Cancer

This Week at ASCO GU 2015: Predicting Therapy Response in Metastatic Castration-Resistant Prostate Cancer

Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference

Epic Sciences Appoints Chris Bernard as Chief Commercial Officer

Epic Sciences Announces Presentation of Three Studies on Novel CTC Liquid Biopsy Assays for Metastatic Prostate Cancers and Bladder Cancers at 2015 ASCO GU Cancer Symposium

Epic Team Member, Laura Leitz, Wins Prostate Cancer Foundation Fundraising Award

Personalized Medicine World Conference 2015

Murali Prahalad, Ph.D., president and CEO, will give a presentation entitled, “CTCs Come of Aage as Biomarkers” at the Personalized Medicine World Conference (PMWC) 2015.

Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers

Epic’s San Diego Lab Gains CLIA Certification

Epic Sciences Receives CLIA Certification for its Cancer Diagnostics Laboratory

Epic Sciences to Present at the Piper Jaffray Healthcare Conference

Lung Cancer News Today: Epic Sciences to Present CTC-cfDNA Method for Lung Cancer Analysis

Epic’s no cell left behind™ technology allows for a full assessment of non-small cell lung cancer (NSCLC) biomarkers from a single tube of blood, inclusive of EGFR, KRAS, ALK, MET, RET and ROS1.

Epic Sciences to Present Data on a Combination CTC and cfDNA Assay for Molecular Targets of Non-Small Cell Lung Cancer Therapies at the 26th EORTC-NCI-AACR Symposium

An assay to detect clinically actionable non-small cell lung cancer (NSCLC) biomarkers, including EGFR, KRAS, ALK, MET, RET and ROS1, utilizing both circulating tumor cells (CTC) and circulating free DNA (cfDNA) from a single tube of blood will be described at EORTC-NCI-AACR Symposium.

Detecting PD-L1 in Circulating Tumor Cells Could Improve Immunotherapies

Liquid biopsy, or blood sample tests, under development by Epic Sciences can generate real time information on the presence of PD-L1 protein in tumors by analyzing circulating tumor cells (CTCs). Identifying patients with PD-L1-expressing tumor cells is essential for the new generation of cancer immunotherapies rapidly progressing in clinical trials.

Epic Sciences Appoints Toni Wayne as Vice President of Human Resources

26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Data presented on 1) PD-L1 assay on circulating tumor cells identified in a liquid biopsies from non-small cell lung cancer patients and 2) a new assay for NSCLC biomarkers, including EGFR, KRAS, ALK, MET, RET and ROS1, utilizing both circulating tumor cells (CTC) and circulating free DNA (cfDNA) from a single tube of blood.

Epic Sciences to Present on Characterizing PD-L1 in Circulating Tumor Cells of Non-Small Cell Lung Cancer Patients at the 26th EORTC-NCI-AACR Symposium

PD-L1 protein expression in circulating tumor cells (CTCs) in a liquid biopsy from non-small cell lung cancer (NSCLC) patients — data will be presented at EORTC.

FAQs: Circulating Tumor Cells (CTCs)

Circulating tumor cells (CTCs) are cells that have broken away from a primary tumor and enter the bloodstream. The mere presence of one or more CTC type described above can give us clues about a cancer’s origin, metastatic risk, and prognosis. From a liquid biopsy, Epic’s no cell left behind™ technology can help match patients to therapies for personalized medicine.

November 21: Susan G. Komen 3-Day Walk Tent

Movember 2014: Rock Bottom Party and Teddy Bear Drive

Lung Cancer Awareness Month: What You Should Know About Metastasis

Metastatic cancer is a cancer that has spread through the bloodstream or lymphatic system from the part of the body where it started to other parts of the body. Circulating tumor cells are pivotal to understanding the biology of metastasis and promise potential as a biomarker to, noninvasively through a liquid biopsy, evaluate tumor progression and response to treatment, especially in lung cancer where tissue biopsies are difficult to obtain.

ESMO 2014

Epic Sciences Appoints Glen Freiberg as Vice President of Regulatory Affairs and Quality Assurance

Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine

Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors

Cancer Discovery: Tracking CTCs May Improve Cancer Treatment

Epic Sciences Selected to Present at Cavendish Global Health Impact Forum

Epic Sciences Appoints Pascal Bamford, Ph.D. as Vice President of Product Development